Copyright ©The Author(s) 2023.
World J Clin Oncol. Apr 24, 2023; 14(4): 138-159
Published online Apr 24, 2023. doi: 10.5306/wjco.v14.i4.138
Table 1 Ongoing and completed clinical trials of oncolytic virus therapy in glioblastoma
NCT Number
Enrolled patients
NCT03714334DNX-2440 Oncolytic Adenovirus for Recurrent GlioblastomaUnknown status24Drug: DNX-2440 injectionSpainPhase 1
NCT03294486Safety and Efficacy of the oncolytic virus Armed for Local Chemotherapy, TG6002/5- FC, in Recurrent Glioblastoma PatientsUnknown status78Drug: Combination of TG6002 and 5- flucytosine (5-FC, Ancotil®)FrancePhase 1 and 2
NCT02197169DNX-2401 With Interferon Gamma (IFN-#) for Recurrent Glioblastoma or Gliosarcoma Brain TumorsCompleted37Drug: Single intratumoral injection of DNX-2401; Drug: Interferon-gammaUnited StatesPhase 1
NCT01956734Virus DNX2401 and Temozolomide in Recurrent GlioblastomaCompleted31Procedure: DNX2401 and TemozolomideSpainPhase 1
NCT05095441A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive GlioblastomaNot yet recruiting51Biological: C5252United StatesPhase 1
NCT01174537New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and NeuroblastomaWithdrawn0Biological: New castle disease virusIsraelPhase 1 and 2
NCT01491893PVSRIPO for Recurrent Glioblastoma (GBM)Completed61Biological: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)United StatesPhase 1
NCT00028158Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain CancerCompleted 65Drug: G207, an oncolytic virusNot providedPhase 1 and 2
NCT03896568MSC-DNX-2401 in Treating Patients With Recurrent High Grade GliomaRecruiting36Biological: Oncolytic Adenovirus Ad5- DNX-2401; Procedure: Therapeutic conventional surgeryUnited StatesPhase 1
NCT01582516Safety Study of Replication competent Adenovirus (Delta-24-rgd) in Patients With Recurrent GlioblastomaCompleted 20Biological: Delta-24- RGD adenovirusNetherlandsPhase 1 and 2
NCT03072134Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant GliomaCompleted 13Biological: Neural stem cells loaded with an oncolytic adenovirusUnited StatesPhase 1
NCT013014300 Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.Completed18Drug: H-1PVGermanyPhase 1 and 2
NCT05084430Study of Pembrolizumab and M032 (NSC 733972)Active, not recruiting28Drug: M032; Drug: Pembrolizumab United StatesPhase 1 and 2
NCT02031965Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By SurgeryTerminated2Biological: Oncolytic HSV-1716; Drug: Dexamethasone; Procedure: Therapeutic conventional surgeryUnited StatesPhase 1
NCT02798406Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompleted49Biological: DNX-2401; Biological: Pembrolizumab United StatesPhase 2
NCT03657576Trial of C134 in Patients With Recurrent GBMActive, not recruiting24Biological: C134United StatesPhase 1
NCT03152318A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Recruiting62Drug: rQNestin; Drug: Cyclophosphamide Procedure: Stereotactic biopsy United StatesPhase 1
NCT03043391Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in ChildrenActive, not recruiting12Biological: Polio/ Rhinovirus Recombinant (PVSRIPO)United StatesPhase 1
NCT05139056Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAdS-pk7) for the Treatment of Recurrent High-Grade GliomasWithdrawn0Biological: Neural Stem Cells expressing CRAdS-pk7; Procedure: ResectionNot providedPhase 1
NCT02062827Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant GliomaActive, not recruiting24Biological: M032 (NSC 733972)United StatesPhase 1
NCT04482933HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade GliomaNot yet recruiting40Drug: Biological G207United StatesPhase 2
NCT02986178PVSRIPO in Recurrent Malignant GliomaActive, not recruiting122Biological: PVSRIPOUnited StatesPhase 2
NCT03911388HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruiting15Biological: G207United StatesPhase 1
NCT02457845HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain TumorsActive, not recruiting13Biological: G207United StatesPhase 1
NCT00528684Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant GliomasCompleted18Biological: REOLYSIN®United StatesPhase 1
NCT03973879Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaWithdrawn0Biological: PVSRIPO; Drug: Atezolizumab Not providedPhase 1 and 2
NCT00314925Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine FeaturesUnknown status60Drug: Seneca Valley virus (biological agent)United StatesPhase 1